FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204258569> ?p ?o ?g. }

• W3204258569 abstract "Abstract Objective To compare the efficacy of COVID 19 vaccines between those with immunocompromised medical conditions and those who are immunocompetent Design Systematic review and meta-analysis Data sources PubMed, EMBASE, CENTRAL, CORD-19 and WHO COVID-19 research databases were searched for eligible comparative studies published between 1 December 2020 and 3 September 2021. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched in September 2021 to identify registered yet unpublished or ongoing studies. Study selection Prospective observational studies which compared the efficacy of COVID-19 vaccination between those with immunocompromising medical conditions and those who were immunocompetent were included. Two reviewers independently screened for potentially eligible studies. Data extraction The primary outcomes of interest were cumulative incidence of seroconversion after first and second doses of COVID vaccination. Secondary outcomes included SARS-CoV-2 antibody titre level after first and second doses of COVID-19 vaccination. After duplicate data abstraction, a frequentist random effects meta-analysis was conducted. Risk of bias was assessed using the ROBINS-I tool. Certainty of evidence was assessed using the GRADE approach. Results After screening 3283 studies, 42 studies that met our inclusion criteria were identified. 18 immunocompromised cohorts from 17 studies reported seroconversion in immunocompromised patients compared to healthy controls after the first dose and 30 immunocompromised cohorts in 28 studies reporting data after the second dose. Among immunocompromised groups, in incremental order, transplant recipients had the lowest pooled risk ratio of 0.06 (95%CI: 0.04 to 0.09, I^2=0%, p=0.81) (GRADE=Moderate) followed by haematological cancer patients at 0.36 (95%CI: 0.21 to 0.62, I^2 = 89%, p<0.01) (GRADE=Moderate), solid cancer patients at 0.40 (95%CI: 0.31 to 0.52, I^2 = 63%, p=0.03) (GRADE=Moderate) and IMID patients at 0.66 (95%CI: 0.48 to 0.91, I^2=81%, p<0.01) (GRADE=Moderate). After the second dose, the lowest pooled risk ratio was again seen in transplant recipients at 0.29 (95%CI: 0.21 to 0.40, I^2=91%, p<0.01) (GRADE=Moderate), haematological cancer patients at 0.68 (95%CI: 0.57 to 0.80, I^2=68%, p=0.02) (GRADE=Low), IMID patients at 0.79 (95%CI: 0.72 to 0.86, I^2=87%, p<0.01) (GRADE=Low) and solid cancer at 0.92 (95%CI: 0.89 to 0.95, I^2=26%, p=0.25) (GRADE=Low). Conclusion Seroconversion rates and serological titres are significantly lower in immunocompromised patients with transplant recipients having the poorest outcomes. Additional strategies on top of the conventional 2-dose regimen will likely be warranted, such as a booster dose of the vaccine. Systematic review registration PROSPERO CRD42021272088" @default.
• W3204258569 created "2021-10-11" @default.
• W3204258569 creator A5002911877 @default.
• W3204258569 creator A5003363190 @default.
• W3204258569 creator A5010217589 @default.
• W3204258569 creator A5023893266 @default.
• W3204258569 creator A5025752496 @default.
• W3204258569 creator A5049834540 @default.
• W3204258569 creator A5053619368 @default.
• W3204258569 creator A5054173026 @default.
• W3204258569 creator A5056406805 @default.
• W3204258569 creator A5067426504 @default.
• W3204258569 creator A5077043443 @default.
• W3204258569 creator A5081871086 @default.
• W3204258569 date "2021-10-01" @default.
• W3204258569 modified "2023-10-12" @default.
• W3204258569 title "Efficacy of COVID-19 vaccines in immunocompromised patients: A systematic review and meta-analysis" @default.
• W3204258569 cites W1568534433 @default.
• W3204258569 cites W1966623111 @default.
• W3204258569 cites W1986976967 @default.
• W3204258569 cites W2143704653 @default.
• W3204258569 cites W2147699808 @default.
• W3204258569 cites W2165010366 @default.
• W3204258569 cites W2531269403 @default.
• W3204258569 cites W2606213316 @default.
• W3204258569 cites W2771500636 @default.
• W3204258569 cites W2918940752 @default.
• W3204258569 cites W2970684805 @default.
• W3204258569 cites W3011609164 @default.
• W3204258569 cites W3017734961 @default.
• W3204258569 cites W3019936966 @default.
• W3204258569 cites W3025232799 @default.
• W3204258569 cites W3092986206 @default.
• W3204258569 cites W3096968677 @default.
• W3204258569 cites W3111255098 @default.
• W3204258569 cites W3112248954 @default.
• W3204258569 cites W3113228067 @default.
• W3204258569 cites W3118615836 @default.
• W3204258569 cites W3126623077 @default.
• W3204258569 cites W3128813257 @default.
• W3204258569 cites W3135966613 @default.
• W3204258569 cites W3136355231 @default.
• W3204258569 cites W3136996256 @default.
• W3204258569 cites W3142193311 @default.
• W3204258569 cites W3154374447 @default.
• W3204258569 cites W3154381950 @default.
• W3204258569 cites W3154998622 @default.
• W3204258569 cites W3155225558 @default.
• W3204258569 cites W3155756133 @default.
• W3204258569 cites W3156866359 @default.
• W3204258569 cites W3157335169 @default.
• W3204258569 cites W3157453497 @default.
• W3204258569 cites W3158750369 @default.
• W3204258569 cites W3158831599 @default.
• W3204258569 cites W3159505699 @default.
• W3204258569 cites W3160666541 @default.
• W3204258569 cites W3160805482 @default.
• W3204258569 cites W3162395942 @default.
• W3204258569 cites W3163785571 @default.
• W3204258569 cites W3164117855 @default.
• W3204258569 cites W3164226705 @default.
• W3204258569 cites W3164547793 @default.
• W3204258569 cites W3164747805 @default.
• W3204258569 cites W3164768289 @default.
• W3204258569 cites W3164898159 @default.
• W3204258569 cites W3165224470 @default.
• W3204258569 cites W3165239056 @default.
• W3204258569 cites W3165390631 @default.
• W3204258569 cites W3166184636 @default.
• W3204258569 cites W3166460483 @default.
• W3204258569 cites W3167220489 @default.
• W3204258569 cites W3170814150 @default.
• W3204258569 cites W3172019122 @default.
• W3204258569 cites W3172347093 @default.
• W3204258569 cites W3173834253 @default.
• W3204258569 cites W3175948812 @default.
• W3204258569 cites W3177279996 @default.
• W3204258569 cites W3179639010 @default.
• W3204258569 cites W3180841149 @default.
• W3204258569 cites W3181407527 @default.
• W3204258569 cites W3182782630 @default.
• W3204258569 cites W3183904285 @default.
• W3204258569 cites W3184885248 @default.
• W3204258569 cites W3186114398 @default.
• W3204258569 cites W3186315581 @default.
• W3204258569 cites W3186535828 @default.
• W3204258569 cites W3187412067 @default.
• W3204258569 cites W3189820169 @default.
• W3204258569 cites W3189930139 @default.
• W3204258569 cites W3190427561 @default.
• W3204258569 cites W3193012584 @default.
• W3204258569 cites W3193104554 @default.
• W3204258569 cites W3193259004 @default.
• W3204258569 cites W3194509710 @default.
• W3204258569 cites W3195116559 @default.
• W3204258569 cites W3197493891 @default.
• W3204258569 cites W3198116064 @default.
• W3204258569 cites W3102969086 @default.
• W3204258569 doi "https://doi.org/10.1101/2021.09.28.21264126" @default.
• W3204258569 hasPublicationYear "2021" @default.

• next